Treatment of schistosomiasis with oltipraz given in one single dose

ABSTRACT

In this study, 152 patients with active S. haematobium and S. mansoni were treated with the relative new non-antimonial oral schistosomicide oltipraz. It was given in one single dose of 25 mg/kg body weight clinical, biological tolerability and drug efficacy were followed up for a period of 12 months. High cures rate ranging between 85 and 96% were obtained. The drug also was well tolerated with no adverse hematological or biochemical effects in schistosomal cases with hepatic fibrosis